Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Mediterr J Rheumatol ; 34(3): 302-314, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37941856

ABSTRACT

In 2017, the Moroccan Society of Rheumatology (SMR) issued guidelines for the treatment of severe ankylosing spondylitis. The emergence of new therapeutic classes, the update of international guidelines for axial SpA and psoriatic arthritis, and the diagnostic and therapeutic challenges encountered by rheumatologists has led to the development of recent SMR guidelines for the management of SpA patients. A group-work included rheumatologists, specialists in physical medicine and rehabilitation, and epidemiologists from various sectors was tasked with writing these recommendations based on a literature review, then adapting them to the national context. Thus, 33 recommendations were selected and organized into two sections: diagnostic and therapeutic. The diagnostic section included three general principles and fourteen recommendations. The first, second, and third recommendations concerned the definition and diagnostic criteria for psoriatic arthritis and psoriatic arthritis. In the management of SpA, Recommendation 4 prioritized the importance of opportunity windows. The recommendation5 concerned the diagnostic and prognostic significance of HLAB27. The sixth and seventh recommendations related to imaging of the sacroiliac joints and the spine. The eighth recommendation focuses on the diagnosis and evaluation of perivascular thrombosis activity. The ninth and tenth recommendations concerned the evaluation of SpA activity and psoriatic arthritis. The eleventh and twelfth recommendations concern the evaluation of function and structural progression. The recommendation number thirteen concerned the diagnosis and treatment of coxitis. Recommendation 14 focuses on the most common co-morbidities and extra-rhinitological manifestations observed in SpA.

2.
Cureus ; 15(10): e47379, 2023 Oct.
Article in English | MEDLINE | ID: mdl-38021870

ABSTRACT

Hodgkin's lymphoma (HL), also known as Hodgkin lymphoma or Hodgkin disease, is a type of malignancy that originates in B lymphocytes, which are a type of white blood cells involved in the immune system. It is characterized by the presence of abnormal Reed-Sternberg cells within the lymph nodes or other lymphoid tissues. Bone involvement of HL is exceptional, which can be localized or part of a disseminated disease. The case of our patient is a Hodgkin's lymphoma initially presenting with a complaint of myalgia. Magnetic resonance imaging and 8F-fluorodeoxyglucose positron emission tomography (FDG PET) played a crucial role in the diagnosis of this rare case.

3.
Mediterr J Rheumatol ; 34(2): 139-151, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37654637

ABSTRACT

The advent of new therapeutic classes and the updating of international recommendations have justified the development of recent recommendations by the Moroccan Society of Rheumatology. Methods Guidelines were drafted by a core steering committee after performing a literature search. A multidisciplinary task force, including three fellows, eleven rheumatologists, a specialist in physical medicine and rehabilitation, an epidemiologist from hospital-university, hospital and liberal sectors and one patient assessed the Best Practice Guidelines using 2 rounds of anonymous online voting by modified Delphi process. Thus, 19 recommendations were developed. Recommendation 1 concerns the therapeutic principles, recommendation 2 insists on the information and education of the patient, recommendation 3 concerns the general measures to be adopted, namely physical activity, smoking cessation and psychological support, recommendation 4 concerns Non-Steroidal Anti-Inflammatory Drugs which constitute the first-line treatment, recommendations 5 to 7 concern the use of analgesics, of general and local corticosteroid therapy and conventional synthetic disease-modifying antirheumatic drugs, recommendations 8 to 13 deal with the use of biologic agents, including new classes and their indications in radiographic and nonradiographic axial and peripheral spondyloarthritis, follow-up and management in case of failure or remission, recommendation 14 deals with the indication for Janus kinase inhibitors drugs, recommendation 15 deals with physical treatment and recommendation 16 deals with the indication of surgery. Recommendations 17 to 19 deal with special situations, namely fibromyalgia, vaccination and pregnancy. A well-defined therapeutic strategy with first- and second-line treatments has been established.

4.
Cureus ; 15(5): e39100, 2023 May.
Article in English | MEDLINE | ID: mdl-37273389

ABSTRACT

Introduction The Assessment of SpondyloArthritis International Society (ASAS) criteria for axial and peripheral spondyloarthritis (SpA) allow for the classification of patients with an age of onset of disease of less than 45 years. However, SpA can start after this age. This study aimed to assess the characteristics of late-onset SpA (SpA>45 years) in the Moroccan registry of biological therapies in rheumatic diseases (RBSMR). Methods A cross-sectional study was conducted using the baseline data of the RBSMR. The protocol for the original RBSMR study was reviewed and approved by the Ethics Committee for Biomedical Research Mohammed V University - Rabat, Faculty of Medicine and Pharmacy of Rabat (approval number for the study was 958/09/19, and the date of approval was September 11, 2019), and all patients had given their written consent. Patients who met the 2009 ASAS criteria for SpA were included. They were divided into two groups: early-onset SpA (≤ 45 years) and late-onset SpA (>45 years). Clinical, biological, radiological, and therapy data of the two groups were compared. Statistical analysis was performed using SPSS v25 software (IBM Corp. Armonk, NY). Parameters with a p-value ≤0.05 were considered significant. Results Our population consisted of 194 patients. Thirty-one patients (16%) had late-onset SpA. Comparison between patients with early-onset (≤45 years) and late-onset SpA (>45 years) revealed that late-onset SpA had a higher tender joint count (p=0.01), a higher swollen joint count (p=0.02), depression (p=0.00), fibromyalgia (p=0.001), hypercholesterolemia (p=0.01), and a lower frequency of coxitis (p=0.008). Logistic regression analysis confirmed that late-onset SpA was associated with a higher tender joint count (OR=0.93, CI 95%: 0.88-0.98), a higher swollen joint count (OR=0.92, CI 95%: 0.85-0.99), depression ( OR=0.19, CI 95%:0.04-0.38), fibromyalgia (OR=1.75, CI 95%: 1.74-17.85), and a lower frequency of coxitis ( OR=0.29, CI 95%: 0.11-0.75). Conclusion As life expectancy increases, late-onset SpA will become increasingly common. It is therefore imperative to determine its characteristics. In the RBSMR study, late-onset SpA was associated with a high number of tender and swollen joints, depression, fibromyalgia, and a lower frequency of coxitis.

6.
Mediterr J Rheumatol ; 33(3): 316-321, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36531422

ABSTRACT

Objectives: To describe and analyse the prevalence of extra-articular manifestations (EAMs) including acute anterior uveitis (AAU), psoriasis and inflammatory bowel disease (IBD) in patients with ankylosing spondylitis (AS) in the Moroccan registry of biological therapies in rheumatic diseases RBSMR (Registre des Biothérapies de la Société Marocaine de Rhumatologie). Methods: A cross-sectional, multicentre and analytical study based on the RBSMR database, which included 170 AS. Incidence rates for the development of AAU, psoriasis and IBD were calculated, and risk factors were analysed. Results: Prevalence of EAMs in AS was 13.5%, 4.7% and 11.2% for AAU, psoriasis and IBD respectively. No significant differences were found while establishing a comparison of the prevalence of these EAMs between AS patients with and without peripheral arthritis. Interestingly, AAU was the most common EAM, and was positively associated in multivariable regression with family history of spondyloarthritis (OR= 7.21, CI 95%: 2.23-23.24). Conclusions: AAU was the leading EAM in patients with AS included in the Moroccan biotherapy registry (RBSMR) and it was associated with family history of spondyloarthritis.

7.
Rheumatol Int ; 41(9): 1625-1631, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34173843

ABSTRACT

Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Axial Spondyloarthritis/epidemiology , Latent Tuberculosis/drug therapy , Adult , Arthritis, Rheumatoid/epidemiology , Biological Products/therapeutic use , Comorbidity , Female , Humans , Latent Tuberculosis/diagnosis , Latent Tuberculosis/epidemiology , Male , Middle Aged , Morocco/epidemiology , Prevalence , Registries , Retrospective Studies , Tuberculin Test/statistics & numerical data
8.
Pan Afr Med J ; 38: 183, 2021.
Article in English | MEDLINE | ID: mdl-33995789

ABSTRACT

INTRODUCTION: the aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. METHODS: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized. RESULTS: a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3rd position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type. CONCLUSION: our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/drug therapy , Rituximab/administration & dosage , Adult , Biological Therapy/methods , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Morocco , Registries , Retrospective Studies , Tumor Necrosis Factor-alpha/antagonists & inhibitors
9.
Rheumatol Int ; 35(11): 1889-94, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26248534

ABSTRACT

The aim of the present study was to determine the prevalence of human leukocyte antigen HLA-B27 in Moroccan healthy controls and in patients with ankylosing spondylitis (AS), and to analyze the correlation between HLA-B27 and AS in Moroccan patients. The prevalence of HLA-B27 was determined by evaluating the number of HLA-B27-positive samples in 128 healthy subjects and in 53 patients diagnosed with AS according to the ESSG and AMOR criteria. HLA-B27 was determined by the polymerase chain reaction using sequence-specific primers. Multivariate analysis of our data (HLA-B27, age, sex, and family history) for AS and healthy controls was performed by multiple correspondence analysis (MCA). The frequency of HLA-B27 was significantly greater in AS patients (45.3 %) than in healthy controls (4.7 %) [p < 0.0001, OR 16.8, and CI 95 % (5.83-51.03)]. In addition, HLA-B27 was more common in male patients than in female ones (p < 0.05). 100 % of the AS patients reported a family history of AS, whereas only 20 % of the healthy controls reported a family history of AS. The graphical interpretation of MCA showed a significant relation between the presence of HLA-B27 and AS. This study strengthens the link between HLA-B27 and AS and represents a very valuable informative diagnostic tool, especially in regard to male patients who have a family history of AS.


Subject(s)
HLA-B27 Antigen/genetics , Spondylitis, Ankylosing/genetics , Adolescent , Adult , Black People/genetics , Case-Control Studies , Chi-Square Distribution , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Morocco/epidemiology , Multivariate Analysis , Odds Ratio , Phenotype , Polymerase Chain Reaction , Risk Assessment , Risk Factors , Sex Distribution , Sex Factors , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/ethnology , Spondylitis, Ankylosing/immunology , Young Adult
10.
Pain Med ; 14(2): 287-92, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23241023

ABSTRACT

OBJECTIVE: We conducted a telephonic survey to determine the prevalence of chronic pain with neuropathic characteristics (NC) in the Moroccan general population. DESIGN: We performed a large nationwide telephonic survey based upon a random sampling of households in the 16 administrative regions of Morocco to determine the prevalence of chronic pain with NC in the general population. We used a stratified sampling taking into account the number of residents in each region. A sample of households was drawn for each of the 16 regions using systematic sampling. OUTCOME MEASURES: A questionnaire aimed at identifying chronic pain (defined as daily pain for at least 3 months), evaluating its intensity, duration, and body locations was used. The Moroccan validated version of DN4 questionnaire was used to identify neuropathic characteristics. RESULTS: A total of 5,328 respondents participated in the survey. 21% of the respondents (1,074) (95%CI: 19,9-22,2), reported chronic daily pain for more than 3 months. The point prevalence of chronic pain with NC, was 10.6% (95% CI: 9,75-11,45). The prevalence was higher in women and individuals older than 60. Chronic pain with NC was significantly more prevalent in women, elderly, illiterate respondents, and respondents from lower social class. It was more frequently located in the lower limbs, and its intensity and duration were higher in comparison with chronic pain without neuropathic characteristics. CONCLUSION: Chronic pain with neuropathic characteristics is probably more prevalent in the general population than was previously thought and is generally more severe than other chronic pain.


Subject(s)
Chronic Pain/epidemiology , Neuralgia/epidemiology , Adult , Age Distribution , Aged , Craniocerebral Trauma/epidemiology , Diabetic Neuropathies/epidemiology , Female , Health Surveys , Humans , Lower Extremity , Male , Middle Aged , Morocco/epidemiology , Prevalence , Severity of Illness Index , Sex Distribution , Smoking/epidemiology , Spinal Injuries/epidemiology , Young Adult
11.
Pain Pract ; 11(2): 139-47, 2011.
Article in English | MEDLINE | ID: mdl-20602717

ABSTRACT

BACKGROUND: Verbal descriptors of pain can provide a basis for distinguishing neuropathic pain (NP) from pain of non-neuropathic origin. Much research has been undertaken to develop screening tools for this purpose. The DN4 questionnaire (NP in four questions), is one of theses tools, which was developed and validated in French in 2005. The purpose of this work is to provide an Arabic, culturally appropriate, reliable, and valid version of the DN4 interview questionnaire for the diagnosis of NP. METHODS: A study was conducted consisting of two phases. In the first phase, translation and cultural adaptation of the questionnaire into dialectal Arabic according to international guidelines was accomplished. The final version was reviewed by an expert panel, then tested on a group of 30 patients. The second phase was the validation of the translated version. The analysis of psychometric properties included reliability (internal consistency, inter-rater agreement) and validity (receiver operating characteristics curve analysis and determination of sensitivity, specificity, and positive and negative predictive values). RESULTS: A sample of 170 subjects (129 women, 75%; age: 49.5 ± 12.4 years), 94 (55.3%) with NP and 76 with non-neuropathic pain was enrolled. The questionnaire was reliable (Cronbach's alpha coefficient: 0.63, inter-rater agreement coefficient: 0.96 [0.94-0.97]) and valid for a cut-off value ≥3 points, which was the best value to discriminate between NP and NNP subjects. DISCUSSION: This study represents the second validation DN4 in a language different from the original after the Spanish adaptation. These results support the high discriminatory value of the DN4 questionnaire for identification of NP.


Subject(s)
Complex Regional Pain Syndromes/diagnosis , Language , Pain Measurement/methods , Peripheral Nervous System Diseases/diagnosis , Surveys and Questionnaires/standards , Translating , Adult , Complex Regional Pain Syndromes/classification , Complex Regional Pain Syndromes/physiopathology , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Middle East , Peripheral Nervous System Diseases/classification , Peripheral Nervous System Diseases/physiopathology
12.
Surg Infect (Larchmt) ; 10(6): 549-51, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19656015

ABSTRACT

BACKGROUND: Deep pelvic abscess is a well-known infective complication in gynecologic practice. However, sacral osteomyelitis has been reported rarely. We describe sacral infection presenting three years after abdominal hysterectomy and point out the difficulty in management. METHODS: Case report and review of the pertinent literature. RESULTS: A 46-year-old woman who had undergone abdominal hysterectomy three years before presented with an 8-month history of abdominopelvic pain recently intensifying in the sitting position without fever. Gynecologic, urinary, and rectal examination did not yield positive findings. An abdominopelvic computed tomography (CT) scan was normal except for sacral osteolysis. A neoplasm was suspected, but magnetic resonance imaging revealed an S2-S4 cystic collection with presacral extension. Neurologic examination did not show any focal deficits. A posterior CT-guided biopsy-aspiration yielded purulent fluid. Pathologic examination revealed inflammatory granulations without any malignant tumor. Abscess cultures grew three microorganisms. The patient's symptoms resolved completely after 3 months of antibiotic therapy. CONCLUSIONS: Sacral osteomyelitis has not been reported previously after abdominal hysterectomy. Early diagnosis was made difficult by the absence of neurologic findings. Such postoperative infection should be considered after pelvic surgery. Minimally invasive needle aspiration may confirm the diagnosis and reduce the necessary extent of surgical intervention.


Subject(s)
Bacterial Infections/diagnosis , Hysterectomy/adverse effects , Osteomyelitis/diagnosis , Pelvic Pain/etiology , Sacrum/pathology , Surgical Wound Infection/diagnosis , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/microbiology , Biopsy , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Osteomyelitis/microbiology , Radiography , Sacrum/diagnostic imaging , Surgical Wound Infection/microbiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...